Imaging of Prostate Cancer

Akın, Oğuz; Hricak, Hedvig

doi:10.1016/j.rcl.2006.10.008

Cited by 94 publications

(59 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been estimated that only 13% to 22% of men who have prostate cancer detected on the basis of the PSA test would benefit from treatment. 3 Current imaging modalities have a limited ability to observe the extent of prostate cancer within the gland 4 and, thus, cannot be used to monitor tumor behavior or the rate of growth. Histologic grading, in the form of the Gleason score, 5,6 is a well established prognostic factor in prostatic cancer but is most powerful at the extreme ends of the spectrum, with high scores from 8 to 10 associated with aggressive disease.…”

mentioning

confidence: 99%

The clinical management of patients with a small volume of prostatic cancer on biopsy: What are the risks of progression?

Harnden

Naylor

Shelley

et al. 2008

Cancer

View full text Add to dashboard Cite

Clinically localized prostate cancer is associated with a wide variation in biologic behavior, and men with the less aggressive form of the disease may never develop symptoms. There has been a rise in prostate cancer incidence in countries in which the blood test for prostatic-specific antigen (PSA) is common, and concerns have been expressed that this may be because of the increased detection of indolent disease, subjecting these men to unnecessary treatment and associated side effects. For the current review, the authors conducted a systematic evaluation of the literature regarding the outcomes of men who were diagnosed on the basis of a small volume of cancer in prostatic biopsies. The results indicated that, despite differences in study design and reporting, a significant proportion of patients with microfocal cancer, regardless of how it was defined, had adverse pathologic findings and a significant risk of PSA recurrence after undergoing radical prostatectomy. Biochemical and clinical recurrences also were observed after radiotherapy or watchful waiting. The authors concluded that patients with microfocal carcinoma on biopsy should be advised that their disease is not necessarily ''insignificant'' and should be counseled accordingly. Cancer 2008; 112:971-81.

show abstract

mentioning

confidence: 99%

The clinical management of patients with a small volume of prostatic cancer on biopsy: What are the risks of progression?

Harnden

Naylor

Shelley

et al. 2008

Cancer

View full text Add to dashboard Cite

show abstract

“…Researchers in numerous studies have suggested that magnetic resonance (MR) imaging, used alone or in combination with functional or metabolic MR imaging techniques, such as MR spectroscopic imaging, can contribute valuable information to the pretreatment assessment of prostate cancer (4,(11)(12)(13)(14)(15)(16)(17)(18). Therefore, the purpose of our study was to prospectively evaluate the diagnostic performance of T2-weighted MR imaging and MR spectroscopic imaging in detecting lesions stratified by pathologic volume and Gleason score in men with clinically determined low-risk prostate cancer.…”

Section: Genitourinary Imaging: Mr Performance Characteristics In Lowmentioning

confidence: 99%

“…With the use of established criteria (11,19,20), each radiologist scored the probability of the presence of tumor on T2-weighted images in each sextant of the prostate (for both peripheral and transition zones) on the following scale: score 1, definitely absent; score score of 6 at biopsy, PSA level of ,10 ng/mL [,10 mg/L]). Management of these patients' cancers depended on discussions between the patient and referring physician and patient choice.…”

Section: Patientsmentioning

confidence: 99%

Performance Characteristics of MR Imaging in the Evaluation of Clinically Low-Risk Prostate Cancer: A Prospective Study

Vargas¹,

Akın²,

Shukla–Dave³

et al. 2012

Radiology

Self Cite

View full text Add to dashboard Cite

Dr(hc) Purpose:To prospectively evaluate diagnostic performance of T2-weighted magnetic resonance (MR) imaging and MR spectroscopic imaging in detecting lesions stratified by pathologic volume and Gleason score in men with clinically determined low-risk prostate cancer. Materials and Methods:The institutional review board approved this prospective, HIPAA-compliant study. Written informed consent was obtained from 183 men with clinically low-risk prostate cancer (cT1-cT2a, Gleason score  6 at biopsy, prostatespecific antigen [PSA] level , 10 ng/mL [10 mg/L]) undergoing MR imaging before prostatectomy. By using a scale of 1-5 (score 1, definitely no tumor; score 5, definitely tumor), two radiologists independently scored likelihood of tumor per sextant on T2-weighted images. Two spectroscopists jointly recorded locations of lesions with metabolic features consistent with tumor on MR spectroscopic images. Whole-mount step-section histopathologic analysis constituted the reference standard. Diagnostic performance at sextant level (T2-weighted imaging) and detection sensitivities (T2-weighted imaging and MR spectroscopic imaging) for lesions of 0.5 cm 3 or larger were calculated. Results:For T2-weighted imaging, areas under the receiver operating characteristic curves for sextant-level detection were 0.77 (reader 1) and 0.82 (reader 2). For lesions of 0.5 cm 3 and ,1 cm 3 , sensitivities were significantly lower when the lesion Gleason score was 6 (0. Conclusion:In men with clinically low-risk prostate cancer, detection of lesions of ,1 cm 3 with T2-weighted imaging is significantly dependent on lesion Gleason score; detection of lesions of 1 cm 3 is significantly better than detection of smaller lesions and is not affected by lesion Gleason score. The role of MR spectroscopic imaging alone in this population is limited.q RSNA, 20121 From the Departments of Radiology (H

show abstract

“…Thus, a combination of therapy and diagnostics (''theragnostics'') may take morphological and functional properties of the tumor into account, also utilizing non-invasive imaging modalities like dynamic contrast-enhanced magnetic resonance imaging (MRI), diffusion-weighted MRI and MR spectroscopy in order to acquire valuable information about metabolic composition, vascularization, hypoxia and structure (Fig. 2), and translate these into a personalized targeted therapy (''theragates'') [4][5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Radiotherapy and inhibition of the EGF family as treatment strategies for prostate cancer: combining theragnostics with theragates

2010

View full text Add to dashboard Cite

Imaging of Prostate Cancer

Cited by 94 publications

References 101 publications

The clinical management of patients with a small volume of prostatic cancer on biopsy: What are the risks of progression?

The clinical management of patients with a small volume of prostatic cancer on biopsy: What are the risks of progression?

Performance Characteristics of MR Imaging in the Evaluation of Clinically Low-Risk Prostate Cancer: A Prospective Study

Radiotherapy and inhibition of the EGF family as treatment strategies for prostate cancer: combining theragnostics with theragates

Contact Info

Product

Resources

About